Remoxy receives FDA complete response letter
This article was originally published in Scrip
Executive Summary
The US FDA has issued Pain Therapeutics/King Pharmaceuticalsa complete response letter for their NDA for Remoxy, an abuse resistant controlled-release form of oxycodone.